Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Wh… (NCT00445952) | Clinical Trial Compass
CompletedNot Applicable
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
Belgium, France, Germany304 participantsStarted 2005-02
Plain-language summary
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
PURPOSE: This natural history study is collecting information about fungal infections of the blood over time from patients with cancer or from patients who have undergone a stem cell transplant.
Who can participate
Age range
18 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Group A:
* Meets any of the following criteria:
* Diagnosis of hematological malignancy including, but not limited to, any of the following:
* Acute lymphoblastic leukemia
* Acute myeloid leukemia
* Myelodysplastic syndromes
* Chronic lymphocytic leukemia
* Diagnosis of solid tumor, including, but not limited to, any of the following:
* Breast cancer (hormone receptor status not specified)
* Lung cancer
* Colon cancer
* Recipient of a hematopoietic stem cell transplantation, including, but not limited to, any of the following:
* Allogeneic or autologous bone marrow transplantation
* Peripheral blood stem cell transplantation
* Admitted to a participating hospital ward (defined as ≥ 1 overnight stay)
* Group B:
* Meets the same criteria as in group A
* Positive blood culture for a fungus
PATIENT CHARACTERISTICS:
* Male or female
* Menopausal status not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior participation in this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Relative incidence of fungemia
2
Fungal species distribution
3
Survival in patients with fungemia
4
Mortality at 2, 4, and 12 weeks after diagnosis of fungemia
Trial details
NCT IDNCT00445952
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC